Welcome to Read AI Digital (RAID)

 Exemplar READ AI products for clinical trial support in Geographic Atrophy, an area of intense interest for clinical trial Sponsors: 

GA-AI Monitor

• Advanced validated models 
• Accurate segmentation of geographic atrophy biomarkers.

GA-AI Predict

• Predicts progression rates for geographic atrophy.
• Offers unique insights into fast vs. slow progressors.

GA-AI Vision

• Links OCT biomarkers to visual acuity and sensitivity.
• Facilitates early detection and intervention.

 Results That Matter
RAID’s AI solutions have demonstrated success in global trials. Our commitment to clinical excellence is validated by independent research and global collaborations. 

Unveiling the Phenopolis Platform

 Central to RAID is the Phenopolis Platform, designed to establish new endpoints correlated with known structure-activity relationships, enabling:

• Early diagnosis of ocular conditions
• Precision in treatment selection
• Predictive monitoring of disease progression

 The acquisition of Phenopolis, a leading developer of “explainable” AI clinical trial management systems (VisionSense), is a key enabler for RAID’s unique and disruptive Medical AI Innovation Hub and digital AI Reading Centre. 

Partner with RAID
 

Elevate the impact of ophthalmic research with our platform. Partnering with RAID, unlocks access to our innovative end-to-end solution for clinical trial support, including: 

• Insights into clinical trial design by leading experts.

• Insights from validated clinical trials.
• A network of global experts and centers.
•  Privacy-protecting AI for decentralised clinical trials (“Federated Learning”) 

Read AI Digital (RAID) combines world-class expertise with cutting-edge AI technology to deliver unparalleled reading center services for clinical trials.